Search

Travel Grants

Travel grant application is now closed. Travel grants are intended to support young investigators to participate in the 7th European CAR T-cell Meeting; therefore, applicants should be 40 years of age or younger.

Read more

EHA Exam

An annual assessment designed to test your knowledge of the European Hematology Curriculum. EHA Exam 2025
The 9th European Hematology Exam will take place on June 12, 2025, from 13:30–16:00 (CEST).

Read more

How to apply for an EHA Kick-off Grant

On this page, we explain all of the actions you'll need to take when submitting an EHA Kick-off Grant application.

Read more

How to apply for an EHA Research Grant

On this page, we explain all of the actions you'll need to take when submitting a grant application. You can also get a basic overview of the process in our EHA Research Grants diagram.

Read more

How to apply for an EHA Innovation Grant

On this page, we explain all of the actions you'll need to take when submitting an EHA Innovation Grant application.

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

What to expect from European Affairs at EHA2024

European Affairs gives a voice to hematology professionals in Europe. The department ensures that the interests of EHA members are duly represented in policy, regulatory and scientific areas and networks.

Read more

Immunoglobulin shortages in the spotlight: EMA, SUPPLY and the SoHO Regulation

EMA executive director Emer Cooke welcoming participants including EHA at the Shortages Workshop, March 1

 

Shortages of immunoglobulins and the need to increase and sustain plasma supplies have moved to the center of the EU policy and regulatory stage.

Read more

Gdf -11 a new target to improve anemia in thalassemia.

 

β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.

Read more